PlainRecalls

Daiichi Sankyo Pharma Development

Compiled from official public sources by the publisher.

8 recalls on record · Latest: Aug 6, 2014

Subscribe to new Daiichi Sankyo Pharma Devel… recalls (RSS)

Agency notice ledger

Federal filing book Daiichi Sankyo Pharma Devel… LIGHT-BOOK · SINGLE-AGENCY

#1,725 of 14,151 · 8 notices · 0.008% archive

  • BOOK 8 notices
  • RANK #1,725 of 14,151
  • SHARE 0.008% archive
  • AGENCY FDA Drug (8)
  • CAT drugs
  • CATS 1 category
  • LATEST Aug 6, 2014
  • PHOTO Ab Sciex

Nearest notice-volume peer: Ab Sciex (0 notice gap)

Daiichi Sankyo Pharma Development accounts for about 0.008% of the 104,423-notice archive on 8 distinct filings — a mid share signal beside absolute volume. FDA · CPSC · USDA FSIS · NHTSA notice stamps for this firm. Read with this firm → · Dominant category → · Similar-volume firm →

How Daiichi Sankyo Pharma Devel… compares to 14,151 recalling firms

Daiichi Sankyo Pharma Development ranks 1,725th of 14,151 tracked firms by distinct recall-event count. Archive size reflects filing volume, not inherent product danger.

Daiichi Sankyo Pharma Devel… vs all firms by recall-notice count

Where this firm's archive sits among every tracked recalling manufacturer

8 1725th of 14151 higher than 12,296 of 14,151 firms

Firms, banded by distinct federal recall-event inventory

Each bar is a band; taller bars hold more firms. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source FDA · CPSC · USDA FSIS · NHTSA federal recall filings · 2026-09-15

Daiichi Sankyo Pharma Devel… in the notice-volume neighbourhood

Distinct federal recall events among this firm and nearest nationwide peers

notices

What this shows Daiichi Sankyo Pharma Development holds about 0.008% of archive notices alongside 8 distinct filings.

Source FDA · CPSC · USDA FSIS · NHTSA filings aggregated by PlainRecalls As of September 2026
FDA Drug Moderate Aug 6, 2014

Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18
FDA Drug Moderate Aug 6, 2014

Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30
FDA Drug Moderate Aug 6, 2014

Benicar HCT Tablets (olmesartan medoxomil, hydrochlorothiazide) 20 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-105-30
FDA Drug Moderate Aug 6, 2014

Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/25 mg, 30 and 90 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-107-30 and NDC 65597-107-90
FDA Drug Moderate Aug 6, 2014

Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30
FDA Drug Moderate Aug 6, 2014

Benicar Tablets (olmesartan medoxomil) 20 mg, 30 and 90 count, Rx Only Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-103-30 and NDC 65597-103-90
FDA Drug Moderate Aug 6, 2014

Benicar Tablets (olmesartan medoxomil) 40 mg, 30 and 90 count, Rx Only Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-104-30 and 65597-104-90
FDA Drug Moderate Aug 6, 2014

Azor Tablets (amlodipine and olmesartan medoxomil) 10 mg*/40 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc. Parsippany, NJ 07054 NDC 65597-113-30

Daiichi Sankyo Pharma Devel… holds a measurable archive slice

Drug and device firms outside this manufacturer and state, matched by notice volume and category footprint.

Frequently Asked Questions

How many federal recall notices name Daiichi Sankyo Pharma Devel…? ▼
PlainRecalls indexes 8 distinct federal recall events naming Daiichi Sankyo Pharma Development, aggregated from FDA, CPSC, USDA FSIS, and NHTSA filings (archive as of September 2026). That count is an issuance inventory, not a hazard score.
Where does Daiichi Sankyo Pharma Devel… sit among other recalling firms? ▼
Daiichi Sankyo Pharma Development ranks #1,725 of 14,151 by distinct recall-event count among 14,151 firms in this archive (87th percentile of firms with fewer notices). Rank tracks filing frequency, not product danger.
Which agency issues most of Daiichi Sankyo Pharma Devel…'s notices? ▼
FDA Drug accounts for 8 of this firm's 8 indexed notices.
What product category dominates Daiichi Sankyo Pharma Devel…'s filing book? ▼
Filings for Daiichi Sankyo Pharma Development span 1 product category, led by drugs. Browse that category archive for peer firms and related notices.
Is a higher notice count more dangerous? ▼
No. Archive size reflects how often federal agencies publish recalls naming the firm — reporting volume, coverage, and product range all move the number. Always verify the individual notice with the issuing agency before acting on a specific product.
Daiichi Sankyo Pharma Development: 8 federal recall notices aggregated from FDA, CPSC, USDA FSIS, and NHTSA filings (lead agency FDA Drug). Verify individual notices with FDA directly before acting on a specific recall.

Firm-level totals aggregate distinct federal recall events naming Daiichi Sankyo Pharma Development; individual notices remain authoritative on each linked recall page.

Methodology · Corrections · FDA · CPSC · USDA FSIS · NHTSA · Archive as of September 2026